Safety of botulinum toxin a in children and adolescents with cerebral palsy in a pragmatic setting

Toxins

Volumn 5, Issue 3, 2013, Pages 524-536

  Papavasiliou, Antigone S ^a   Nikaina, Irene ^a   Foska, Katerina ^a   Bouros, Panagiotis ^a   Mitsou, George ^a   Filiopoulos, Constantine ^a  

^a PENTELI CHILDREN S HOSPITAL   (Greece)

Author keywords

Abobotulinumtoxin A; Adverse events; Botulinum toxin A; Cerebral palsy; Onabotulinumtoxin A; Safety; Spasticity; Treatment

Indexed keywords

BOTULINUM TOXIN A; EMLA; MIDAZOLAM; PETHIDINE;

ADOLESCENT; ADULT; ANOREXIA; ARTICLE; ASPIRATION PNEUMONIA; BREATHING DISORDER; CEREBRAL PALSY; CHILD; CONSTIPATION; DEEP SEDATION; DISEASE SEVERITY; DRUG SAFETY; DYSPHAGIA; DYSTONIA; EPILEPSY; FEMALE; FLU LIKE SYNDROME; GROSS MOTOR FUNCTION CLASSIFICATION SYSTEM; HOSPITALIZATION; HUMAN; HYPERHIDROSIS; HYPERSALIVATION; LETHARGY; LIMB WEAKNESS; MAJOR CLINICAL STUDY; MALE; MUSCLE HYPERTONIA; MUSCLE HYPOTONIA; MUSCLE TONE; OXYGEN SATURATION; PAIN; PALLOR; PRESCHOOL CHILD; RESTLESSNESS; RETROSPECTIVE STUDY; SCHOOL CHILD; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SPASTICITY; SPEECH DISORDER; STRABISMUS; VOMITING; WEAKNESS;

ADOLESCENT; ADVERSE DRUG REACTION REPORTING SYSTEMS; BOTULINUM TOXINS, TYPE A; CEREBRAL PALSY; CHILD; DRUG TOXICITY; FEMALE; GREECE; HUMANS; INCIDENCE; MALE; NEUROMUSCULAR AGENTS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84875175553     PISSN: 20726651     EISSN: None     Source Type: Journal    
DOI: 10.3390/toxins5030524     Document Type: Article

References (34)

1. Yeargin-Allsopp, M.; van Naarden Braun, K.; Doernberg, N.S.; Benedict, R.E.; Kirby, R.S.; Durkin, M.S. Prevalence of cerebral palsy in 8-year-old children in three areas of the United States in 2002: A multisite collaboration. Pediatrics 2008, 121, 547-554.
2. Ziv, I.; Blackburn, N.; Rang, M.; Koreska, J. Muscle growth in normal and spastic mice. Dev. Med. Child. Neurol. 1984, 26, 94-99.
3. Cosgrove, A.P.; Graham, H.K. Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse. Dev. Med. Child. Neurol. 1994, 36, 379-385.
4. Berweck, S.; Heinen, F. Use of botulinum toxin in pediatric spasticity (cerebral palsy). Mov. Disord. 2004, 19, 162-167.
5. Papavasiliou, A.S. Management of motor problems in cerebral palsy: A critical update for the clinician. Eur. J. Paediatr. Neurol. 2009, 13, 387-396.
6. Goldstein, E.M. Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J. Child. Neurol. 2006, 21, 189-192.
7. Love, S.C.; Novak, I.; Kentish, M.; Desloovere, K.; Heinen, F.; Molenaers, G.; O'Flaherty, S.; Graham, H.K. Cerebral Palsy Institute. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: International consensus statement. Eur. J. Neurol. 2010, 17, 9-37.
8. Papavasiliou, A.S.; Rapidi, C.A.; Filiopoulos, C.; Rizou, C.; Skouteli, H. Evaluation of a multimodal management of prematurity-related spasticity. Pediatr. Neurol. 2006, 35, 400-407.
9. Coté, T.R.; Mohan, A.K.; Polder, J.A.; Walton, M.K.; Braun, M.M. Botulinum toxin type A injections: Adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J. Am. Acad. Dermatol. 2005, 53, 407-415.
10. Howell, K.; Selber, P.; Graham, H.K.; Reddihough, D. Botulinum neurotoxin A: An unusual systemic effect. J. Paediatr. Child. Health 2007, 43, 499-501.
11. FDA Notifies Public Adverse Reactions Linked to Onabotulinumtoxin A Use. Ongoing Safety Review of Botox, Botox Cosmetic and Myobloc taking place. Available online: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116857.htm (accessed on 24 June 2011).
12. Naidu, K.; Smith, K.; Sheedy, M.; Adair, B.; Yu, X.; Graham, H.K. Systemic adverse events following botulinum toxin A therapy in children with cerebral palsy. Dev. Med. Child. Neurol. 2010, 52, 139-144.
13. O'Flaherty, S.J.; Janakan, V.; Morrow, A.M.; Scheinberg, A.M.; Waugh, M.C. Adverse events and health status following botulinum toxin type A injections in children with cerebral palsy. Dev. Med. Child. Neurol. 2011, 53, 125-130.
14. Albavera-Hernández, C.; Rodríguez, J.M.; Idrovo, A.J. Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: A systematic review of randomized clinical trials.Clin.Rehabil. 2009, 23, 394-407.
15. Olesch, A.; Greaves, S.; Imms, C.; Reid, S.M.; Graham, H.K. Repeat botulinum toxin-A injections in the upper limb of children with hemiplegia: A randomized controlled trial. Dev. Med. Child. Neurol. 2010, 52, 79-86.
16. Russo, R.N.; Crotty, M.; Miller, M.D.; Murchland, S.; Flett, P.; Haan, E. Upper-limb botulinum toxin A injection and occupational therapy in children with hemiplegic cerebral palsy identified from a population register: A single-blind, randomized, controlled trial. Pediatrics 2007, 119, 1149-1158.
17. Heinen, F.; Molenaers, G.; Fairhurst, C.; Carr, L.; Kolanowski, E.; Morel, E.; Papavassiliou, A.; Tedroff, K.; Pascual, I.; Bernert, G.; et al. European consensus on the role of botulinum toxin in the treatment of cerebral palsy. Eur. J. Paediatr. Neurol. 2006, 10, 215-225.
18. Heinen, F.; Desloovere, K.; Schroeder, A.S.; Berweck, S.; Borggraefe, I.; van Campenhout, A.; Andersen, G.L.; Aydin, R.; Becher, J.G.; Bernert, G.; et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur. J. Paediatr. Neurol. 2010, 14, 45-66.
19. Palisano, R.; Rosenbaum, P.; Walter, S.; Russell, D.; Wood, E.; Galuppi, B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev. Med. Child. Neurol. 1997, 39, 214-23.
20. Papavasiliou, A.S.; Rapidi, C.A.; Rizou, C.; Petropoulou, K.; Tzavara, C. Reliability of Greek version gross motor function classification system. Brain Dev. 2007, 29, 79-82.
21. Rystedt, A.; Nyholm, D.; Naver, H. Clinical experience of dose conversion ratios between 2 botulinum toxin products in the treatment of cervical dystonia. Clin. Neuropharmacol. 2012, 35, 278-282.
22. Truong, D. Botulinum toxins in the treatment of primary focal dystonias. J. Neurol. Sci. 2012, 316, 9-14.
23. Bakheit, A.M. Botulinum toxin in the management of childhood muscle spasticity:Comparison of clinical practice of 17 treatment centers. Eur. J. Neurol. 2003, 10, 415-419.
24. Kinnett, D. Botulinum toxin A injections in children: Technique and dosing issues.Am. J. Phys. Med. Rehabil. 2004, 83, S59-S64
25. Brochard, S.; Blajan, V.; Lempereur, M.; Garlantezec, R.; Houx, L.; le Moine, P.; Peudenier, S.; Lefranc, J.; Rémy-Néris, O. Determining the technical and clinical factors associated with pain for children undergoing botulinum toxin injections under nitrous oxide and anesthetic cream. Eur. J. Paediatr. Neurol. 2011, 15, 310-315.
26. Bakheit, A.M.; Severa, S.; Cosgrove, A.; Morton, R.; Roussounis, S.H.; Doderlein, L.; Lin, J.P. Safety profile and efficacy of botulinum toxin A (Abobotulinumtoxin A) in children with muscle spasticity. Dev. Med. Child. Neurol. 2001, 43, 234-238.
27. Pascual-Pascual, S.I.; Pascual-Castroviejo, I. Safety of botulinum toxin type A in children younger than 2 years. Eur. J. Paediatr. Neurol. 2009, 13, 511-515.
28. Sławek, J.; Madaliński, M.H.; Maciag-Tymecka, I.; Duzyński, W. Frequency of side effects after botulinum toxin A injections in neurology, rehabilitation and gastroenterology. Pol. Merkur. Lekarski 2005, 18, 298-302.
29. Lowe, K.; Novak, I.; Cusick, A. Repeat injection of botulinum toxin A is safe and effective for upper limb movement and function in children with cerebral palsy. Dev. Med. Child Neurol. 2007,49, 823-829.
30. Willis, A.W.; Crowner, B.; Brunstrom, J.E.; Kissel, A.; Racette, B.A. High dose botulinum toxin A for the treatment of lower extremity hypertonicity in children with cerebral palsy. Dev. Med. Child Neurol. 2007, 49, 818-822.
31. Aoki, K.R.; Ismail, M.; Tang-Liu, D.; Brar, B.; Wheeler, L.A. Botulinum toxin type A: From toxin to therapeutic agent. Eur. J. Neurol. 1997, 4, S1-S3.
32. Awaad, Y.; Tayem, H.; Munoz, S.; Thomas, R.; Soliman, S.; Michon, A.; Minarik, S. High dose of botulinum toxin type-A (BTX/A): Safety and efficacy in patients with cerebral palsy. J. Pediatr. Neurol. 2000, 2, 91-96.
33. Molenaers, G.; van Campenhout, A.; Fagard, K.; de Cat, J.; Desloovere, K. The use of botulinum toxin A in children with cerebral palsy, with a focus on the lower limb. J. Child. Orthop. 2010, 4, 183-195.
34. Adair, B.; Graham, K. Systemic adverse events following injection of botulinum toxin A (BoNT-A) in children with cerebral palsy. Dev. Med. Child. Neurol. 2009, 51, 54-55.